JNJ
T3Johnson & Johnson
OverviewJohnson & Johnson is a global healthcare company that develops and sells pharmaceuticals and medical technologies. Its Innovative Medicine segment (approx. 65%
Johnson & Johnson is a global healthcare company that develops and sells pharmaceuticals and medical technologies. Its Innovative Medicine segment (approx. 65% of Q2 2026 sales) focuses on areas like oncology and immunology, while its MedTech segment (approx. 35%) provides surgical, orthopedic, and vision products. J&J serves patients and healthcare providers worldwide, aiming for consistent long-term growth.
- What They Do (Plain English & Analogies)
- Johnson & Johnson is like a big healthcare supermarket. Instead of selling groceries, they sell a wide range of products and services to help people stay healthy and treat illnesses. They have two main aisles: * **Innovative Medicine:** This aisle is full of advanced prescription drugs, like powerful treatments for cancer, immune system problems, and brain disorders. Think of these as specialized, high-tech medicines developed through a lot of scientific research. * **MedTech:** This aisle offers medical devices and technologies used by doctors and surgeons. This includes things like tools for heart procedures, surgical instruments, and contact lenses. Imagine these as the sophisticated gadgets and equipment that help doctors perform operations or improve vision. They are constantly researching and developing new solutions to tackle complex health challenges, aiming to improve and save lives.
- Very Brief History
- Johnson & Johnson was founded in 1887 by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in New Brunswick, NJ. Over its 140-year history, it has grown into a global healthcare organization, evolving to focus on innovative pharmaceuticals and medical technologies, and recently spinning off its consumer health business.
- "Street Stereotype"
- The street stereotype for Johnson & Johnson is generally that of a stable, diversified, and established pharmaceutical and medical technology giant. Investors and analysts often perceive it as a reliable long-term investment, leveraging its scale, robust R&D pipeline, and strategic acquisitions to drive consistent growth, particularly in high-margin areas like oncology and immunology. While facing some competitive pressures and occasional segment-specific headwinds, the company is seen as having strong execution capabilities and a clear path to future innovation and market leadership.
- Subsidiaries On Linked In*
- Johnson & Johnson Innovative Medicine — Focuses on pharmaceuticals; LinkedIn: johnson-johnson-innovative-medicine
- Johnson & Johnson MedTech — Focuses on medical devices and technology; LinkedIn: johnson-johnson-medtech
- Customer Sectors & Example Clients
- Johnson & Johnson's customers primarily operate within the healthcare sector. These include: * **Hospitals and Healthcare Systems:** For their MedTech products (surgical instruments, cardiovascular devices, orthopedic implants) and many Innovative Medicine products. * **Clinics and Physician Practices:** For specialized medical devices and pharmaceutical treatments. * **Pharmacies:** For dispensing their pharmaceutical products to patients. * **Patients:** Directly for some vision care products (contact lenses) and indirectly for all their pharmaceutical and MedTech offerings. * **Government Health Agencies:** As purchasers and regulators of healthcare products. Specific client *companies* are not named in the transcript, as J&J sells to a broad network of healthcare providers globally. However, based on their business model, their clients would be major hospital chains (e.g., HCA Healthcare, Mayo Clinic), large pharmacy benefit managers (e.g., CVS Caremark, Express Scripts), and national healthcare systems (e.g., NHS in the UK).
- New Customers / Segments They'Re Targeting
- JNJ is actively targeting several new customer segments and expanding within existing ones: * **Patients with Warm Autoimmune Hemolytic Anemia (wAIHA):** With the anticipated FDA approval of IMAAVY, they are targeting patients with this rare and serious autoantibody disease. * **Patients with Relapsed Refractory Multiple Myeloma (earlier lines of therapy):** Expanding the use of CARVYKTI and TECVAYLI in earlier treatment lines. * **Patients with High-Risk Localized Prostate Cancer:** With ERLEADA, targeting treatment before and after surgery to reduce metastasis or death. * **Patients with Head and Neck Cancer:** Expanding RYBREVANT's indications beyond lung cancer. * **Patients with Bladder Cancer (BCG-experienced and BCG-naive):** Expanding INLEXZO's reach from BCG unresponsive patients to larger populations, including high-risk papillary and ultimately BCG naive patients, and developing a device for intermediate-risk non-muscle invasive bladder cancer. * **Patients with Psoriatic Arthritis, Ulcerative Colitis, and Crohn's Disease:** Expanding ICOTYDE's indications beyond psoriasis and further solidifying TREMFYA's position in IBD, including perianal fistulizing Crohn's. * **Patients with Bipolar Mania:** With CAPLYTA, targeting this indication for continued momentum. * **AFib Patients (with better bleeding profile):** With milvexian, targeting AFib patients who are currently not receiving anticoagulants due to bleeding concerns. * **Surgeons seeking advanced robotic systems:** With OTTAVA (table-integrated robotic surgical system) and MONARCH (for Urology), targeting surgeons looking for next-generation surgical technologies. * **Cataract and Presbyopia Patients:** Expanding availability of TECNIS PureSee intraocular lens.
- Supply Chain And Sourcing Geographies
- The transcript mentions "China inventory" impacting electrophysiology growth, suggesting China is a significant geography for either manufacturing, distribution, or sales within their MedTech supply chain. It also refers to "tariffs in the MedTech business" and "anticipated reduction and recoupment of certain tariff-related costs," which implies sourcing or manufacturing from regions subject to tariffs, likely China. Beyond these specific mentions, the transcript does not provide detailed information on the geographical sourcing of raw materials or manufacturing locations for its diverse product portfolio. Given J&J's global operations, it is highly probable they maintain a diversified global supply chain.
- Sales Geographies And Expansion Plans
- Johnson & Johnson has a global sales presence. In Q2 2026, U.S. sales grew 7.3%, and sales outside the U.S. grew 3.4%. **Current Sales Geographies (explicitly mentioned or implied):** * **United States:** Strong growth and numerous product launches/approvals (e.g., TECNIS PureSee, THERMOCOOL SMARTTOUCH SF, CAPLYTA, IMAAVY, OTTAVA, CARTOSOUND SONATA, VARIPULSE Pro, CARVYKTI, INLEXZO). * **Outside U.S. (OUS):** General growth, including sustained adoption of Impella 5.5. * **EMEA (Europe, Middle East, Africa):** Anticipated launch of ETHICON 4000 and continued adoption of VARIPULSE Pro. * **China:** Mentioned in relation to inventory dynamics in electrophysiology and VBP (Volume-Based Procurement) impacting surgery. * **Worldwide:** VARIPULSE platform, Shockwave C2 Aero global launch. **Expansion Plans:** JNJ plans to expand sales globally, with specific mentions of continued rollout of TECNIS PureSee, global adoption of new MedTech platforms, and continued launch uptake of Innovative Medicine products in all regions. They are also investing over $1 billion to scale U.S. Vision manufacturing, packaging, and distribution capabilities to meet growing demand.
- How Key Themes May Help/Hurt
- The "Biotech '26: Established Pharma" theme has a "LONG" position orientation, suggesting bullish upside. JNJ is well-positioned to benefit from the theme's bullish aspects: * **Leveraging cutting-edge research (Bull1):** JNJ's Innovative Medicine segment is actively engaged in genomics and personalized medicine through products like CARVYKTI, bispecific antibodies (TECVAYLI, TALVEY), and targeted therapies (ICOTYDE, INLEXZO, Firefly Bio acquisition for KRAS-driven solid tumors). * **Robust pipeline for rare disease treatments (Bull2):** JNJ is targeting rare diseases like warm autoimmune hemolytic anemia with IMAAVY, which offers high-margin opportunities. * **Strategic partnerships and acquisitions (Bull3):** JNJ's recent acquisitions of Ambrx and Firefly Bio, and collaborations, directly support expanding their portfolio and enhancing R&D capabilities. However, JNJ is also exposed to the theme's potential downsides: * **Regulatory uncertainties (Bear1):** Delays in approvals (e.g., for OTTAVA, VARIPULSE Pro) or shifts in healthcare policies could impact revenue growth. * **Increased competition (Bear2):** JNJ is experiencing this with STELARA biosimilar competition, "competitive PFA pressures" in electrophysiology, and competition in surgical vision. * **Market volatility and economic uncertainties (Bear3):** JNJ considers the "broader macroeconomic environment" and "external factors" in its guidance, indicating awareness of these risks.
3 Main Long-Term Bull Details
- Robust and Diversified Pipeline & Portfolio: JNJ boasts the "strongest portfolio and pipeline in our 140-year history," with 28 products/platforms each generating over $1 billion in annual sales. This breadth, spanning Innovative Medicine (oncology, immunology, neuroscience) and MedTech (cardiovascular, surgery, vision), provides resilience against individual product setbacks and fuels consistent growth, with a clear line of sight to double-digit growth by the end of the decade.
- Strategic Innovation and Acquisitions: The company is continuously investing in R&D and pursuing strategic acquisitions (e.g., Ambrx, Firefly Bio) to strengthen its leadership in next-generation innovation, particularly in oncology (targeting KRAS-driven solid tumors) and advanced MedTech (OTTAVA robotic system). This commitment ensures a steady stream of new, differentiated products addressing high unmet medical needs.
- Market Leadership and Expansion in Key Growth Areas: JNJ holds global leadership positions in areas like electrophysiology and multiple myeloma treatments, and is rapidly gaining share in immunology (TREMFYA in IBD) and new oncology launches (ICOTYDE, INLEXZO, CARVYKTI). The company is also expanding into new indications and patient populations, such as bladder cancer with INLEXZO and warm autoimmune hemolytic anemia with IMAAVY, further solidifying its market presence and growth potential.
3 Main Long-Term Bear Details
- Biosimilar Competition and Patent Expirations: The significant decline in STELARA sales due to biosimilar competition highlights the ongoing risk of patent expirations impacting revenue from established blockbuster drugs. This necessitates continuous pipeline replenishment to offset losses.
- MedTech Segment Headwinds and Clinical Trial Scrutiny: The MedTech segment, particularly Abiomed's heart recovery business, experienced a decline due to physician selectivity following an external clinical trial. While JNJ views this as temporary, it underscores the vulnerability of medical device sales to clinical data interpretation and competitive pressures, which can impact growth trajectories.
- High Investment in New Launches and R&D Impacting Margins: While essential for long-term growth, increased investments in new product launches (e.g., ICOTYDE, MedTech commercial investments) and R&D can put pressure on operating margins in the short to medium term, as seen with the slight decline in Innovative Medicine and MedTech margins in Q2 2026.
- Competitors And Differentiation
- JNJ faces competition across its diverse portfolio: * **Immunology:** Competitors for TREMFYA and ICOTYDE include other IL-23 inhibitors and advanced therapies (e.g., SKYRIZI, "other competitive IL-23s"). JNJ differentiates TREMFYA as a "first-choice biologic" and ICOTYDE as a "first-choice systemic treatment," especially for psoriatic arthritis involvement, and highlights TREMFYA's subQ induction for convenience. * **Oncology:** JNJ aims to be the number one oncology company by 2030, leveraging a deep portfolio with treatments in every line of therapy for multiple myeloma. * **Cardiovascular (Electrophysiology):** Faces "competitive PFA pressures." JNJ differentiates with VARIPULSE, CARTOSOUND SONATA (AI-powered imaging), and the dual-energy THERMOCOOL SMARTTOUCH SF platform. * **Heart Recovery (Abiomed):** While currently the only player in heart pumps, it faces scrutiny from external clinical trials. JNJ differentiates through its pioneering role, extensive clinical evidence base, and ongoing robust clinical research like PROTECT IV. * **Surgery (Robotics):** Competes against an "existing incumbent" (likely Intuitive Surgical). JNJ differentiates OTTAVA with its "unique architecture, automated features, and next-generation robotic instruments" and integration with the Polyphonic open digital ecosystem. MONARCH for Urology is positioned as a "first-of-kind opportunity." * **Anticoagulants:** For milvexian, JNJ aims to differentiate by offering a "better bleeding profile than the current anticoagulants," addressing the unmet need of patients unable to take existing options due to bleeding risk. Overall, JNJ's competitive positioning is built on its "unique combination of scientific expertise, scale, and disciplined execution," a "strongest portfolio and pipeline in our 140-year history," and a commitment to innovation across the full spectrum of healthcare.
- Recent Performance & What The Market'S Focused On
- Johnson & Johnson delivered a strong second quarter in 2026, beating both top and bottom-line estimates and raising its full-year guidance. Worldwide sales were $25.3 billion, an operational growth of 5.6% (double-digit growth excluding STELARA). Adjusted diluted EPS increased by 4.7% to $2.90. The market is focused on: * **Momentum of New Product Launches:** Particularly the strong uptake of ICOTYDE in psoriasis (11,000+ patients, 6,000 unique prescribers), INLEXZO in bladder cancer (1 in 3 eligible patients, 75% new patient insertions growth), and continued high double-digit growth from CARVYKTI, TECVAYLI, and TALVEY in oncology. * **Innovative Medicine Growth Drivers:** The continued strong performance of key brands like DARZALEX (up 17.6%) and TREMFYA (up 71% driven by IBD launch), and the overall segment's 6.8% operational growth despite STELARA headwinds. * **MedTech Recovery and Innovation:** While MedTech growth was 3.6% and cardiovascular (especially Abiomed) saw some headwinds, the market is watching for the acceleration of performance in the second half, driven by new launches like OTTAVA (robotic surgical system), CARTOSOUND SONATA, and Shockwave C2 Aero. The mid-2027 separation of the DePuy Synthes orthopedics business is also a focus. * **Full-Year Guidance and Long-Term Outlook:** JNJ raised its operational sales growth guidance to 6.5%-7.1% (midpoint $100.6 billion) and adjusted operational EPS to $11.50-$11.65. The company's confidence in achieving double-digit growth by the end of the decade and the upcoming enterprise business review in December are key points of interest.
- Revenue Segments And Estimated Mix
- Innovative Medicine — Mix: ~64.8%; Source: Q2 2026 transcript, $16.4 billion out of $25.3 billion total sales; Trend: Increased 6.8% operationally, primary growth engine, strong growth despite STELARA headwind
- MedTech — Mix: ~35.2%; Source: Q2 2026 transcript, $8.9 billion out of $25.3 billion total sales; Trend: Increased 3.6% operationally, lower than recent trend in cardiovascular, expected to improve in H2
- Product Brands
- ICOTYDE
- INLEXZO
- RYBREVANT
- STELARA
- DARZALEX
- CARVYKTI
- TECVAYLI
- TALVEY
- ERLEADA
- TREMFYA
- IMAAVY
- SPRAVATO
- CAPLYTA
- VARIPULSE
- CARTOSOUND SONATA
- THERMOCOOL SMARTTOUCH SF
- Shockwave C2 Aero
- Impella 5.5
- OTTAVA
- ETHICON 4000
- TECNIS PureSee
- ACUVUE
- ACUVUE OASYS 1-Day
- VOLT
- LAZCLUZE
- pasritamig
- J&J 6143
- MONARCH
- ACUVUE OASYS MAX
Bull / Bear DetailsJohnson & Johnson is demonstrating strong operational execution and pipeline momentum, particularly in Innovative Medicine, driving accelerated growth towards d
Thesis
Johnson & Johnson is demonstrating strong operational execution and pipeline momentum, particularly in Innovative Medicine, driving accelerated growth towards double-digits by the decade's end. While facing biosimilar competition for STELARA and temporary MedTech headwinds (Abiomed), successful new product launches (ICOTYDE, INLEXZO, TREMFYA) and strategic acquisitions position JNJ as a medical innovation powerhouse. The company's diversified portfolio and robust pipeline underpin a compelling long-term growth story as of July 17, 2026.
Bull case
JNJ's Innovative Medicine segment is driving significant growth with a robust pipeline and successful new launches like ICOTYDE and INLEXZO, which are outpacing competitors. The company is on track to be the #1 oncology company by 2030, with sales projected to exceed $50 billion, supported by strong performers like DARZALEX and strategic acquisitions such as Firefly Bio.
JNJ boasts a highly diversified portfolio with 28 platforms each generating over $1 billion in annual sales, providing resilience against product-specific headwinds. TREMFYA is a market leader in IBD with over 70% growth, and MedTech innovations like VARIPULSE and the upcoming OTTAVA robotic system reinforce leadership in key healthcare areas, ensuring consistent, broad-based growth.
JNJ delivered a strong Q2 2026, exceeding expectations and raising full-year guidance for operational sales and adjusted EPS. Management projects accelerated growth into 2027 and double-digit growth by the end of the decade, supported by robust free cash flow approaching $21 billion and strategic capital allocation, including continued R&D investment.
Bear case
The significant decline in STELARA sales (55.7% in Q2) due to biosimilar competition highlights the ongoing risk of patent expirations impacting key revenue drivers. This necessitates continuous pipeline replenishment and successful new launches to offset future losses from other established products, posing a constant challenge to maintaining top-line growth.
While overall MedTech growth is positive, specific areas like Abiomed faced a 2% decline in Q2 due to physician caution following a neutral clinical trial. Although management views this as temporary, it underscores the sensitivity of MedTech performance to clinical data and competitive pressures, requiring strong evidence reinforcement and potentially impacting near-term growth.
Despite a positive outlook, the healthcare industry remains subject to regulatory uncertainties and potential shifts in healthcare policies, which could impact drug approval timelines and reimbursement rates. Market volatility and economic uncertainties may also affect investment in R&D and delay the commercialization of new therapies, impacting near-term financial performance.
Bull / Bear Case
- Bear Case
- The significant decline in STELARA sales (55.7% in Q2) due to biosimilar competition highlights the ongoing risk of patent expirations impacting key revenue drivers, necessitating continuous pipeline replenishment to offset future losses. While overall MedTech growth is positive, specific areas like Abiomed faced a 2% decline in Q2 due to physician caution following a neutral clinical trial, underscoring the sensitivity of MedTech performance to clinical data and competitive pressures. Despite management's view that this is temporary, it could impact near-term growth. The healthcare industry also remains subject to regulatory uncertainties and potential shifts in healthcare policies, which could affect drug approval timelines and reimbursement rates, while increased investments in new launches and R&D may pressure operating margins in the short term.
- Bull Case
- Johnson & Johnson's Innovative Medicine segment is a powerful growth engine, driven by a robust pipeline and successful new launches like ICOTYDE and INLEXZO, which are outpacing competitors. The company is on track to become the number one oncology company by 2030, with sales projected to exceed $50 billion, bolstered by strong performers such as DARZALEX and strategic acquisitions like Firefly Bio. JNJ boasts a highly diversified portfolio with 28 platforms each generating over $1 billion in annual sales, providing resilience against product-specific headwinds. TREMFYA is a market leader in IBD with over 70% growth, and MedTech innovations like VARIPULSE and the upcoming OTTAVA robotic system reinforce leadership in key healthcare areas. JNJ delivered a strong Q2 2026, exceeding expectations and raising full-year guidance for operational sales and adjusted EPS, projecting accelerated growth into 2027 and double-digit growth by the end of the decade, supported by robust free cash flow.
- More Compelling & Why
- Bear. JNJ's current P/E ratio of approximately 28-29x is significantly above its 5-year historical average of 21x, suggesting a stretched valuation that already prices in much of the projected future growth. The strongest argument for the bear case is the persistent impact of STELARA biosimilar competition (55.7% decline in Q2) and the temporary, but real, slowdown in the Abiomed MedTech business, which together create near-term revenue headwinds that the market is clearly reacting to with post-earnings underperformance. My view would flip to bullish if the P/E ratio compressed closer to its historical average, or if the MedTech segment, particularly Abiomed, demonstrated a much faster and more robust recovery than currently anticipated, significantly de-risking the growth trajectory.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| TREMFYA IBD Market Share and Growth Trajectory | TREMFYA's exceptional growth and market leadership in inflammatory bowel disease (IBD) are critical for offsetting the impact of STELARA's biosimilar erosion and driving the Innovative Medicine segment's overall performance and long-term growth. | Monitor TREMFYA's operational sales growth, particularly its new patient induction share in ulcerative colitis and Crohn's disease. Watch for continued leadership in these indications (currently 58% in UC and over 50% in CD for IL-23s). | Bullish: Sustained high double-digit sales growth and continued expansion of market share in IBD, reinforcing its position as a key growth driver. Bearish: Significant slowdown in growth or loss of market share to competitors like SKYRIZI. | Johnson & Johnson's quarterly earnings calls and investor presentations. Pharmaceutical market data reports. | Industry analyst reports on immunology market trends; medical conference presentations on IBD treatments. | IQVIA: Prescription data for TREMFYA in IBD; DRG (Decision Resources Group): Market share and competitive intelligence in immunology. |
| OTTAVA Robotic Surgical System FDA Authorization and Launch | OTTAVA represents a significant MedTech innovation, positioning Johnson & Johnson as a major player in the high-growth surgical robotics market. Its successful FDA authorization and commercial launch will drive future MedTech growth and market share. | Monitor for FDA authorization (De Novo classification) for the OTTAVA system, particularly for general surgery procedures in the upper abdomen. Also, watch for details on the commercial launch plans and initial adoption rates. | Bullish: FDA authorization and a successful commercial launch with strong initial surgeon adoption and positive feedback. Bearish: Delays in FDA authorization, or slow adoption post-launch due to competitive pressures or system complexities. | Johnson & Johnson's press releases, MedTech investor updates, and future earnings calls. FDA announcements regarding device clearances. | Industry news and trade publications focused on surgical robotics; social media discussions among surgeons. | Spherix Global Insights: Surgeon surveys on robotic system preferences and adoption; MedPanel: Market research on surgical robotics. |
| Key Innovative Medicine Pipeline Catalysts in H2 2026 | A robust pipeline is essential for sustaining long-term growth, especially with STELARA's decline. Successful regulatory approvals and positive data readouts for key assets like IMAAVY, TECVAYLI combinations, INLEXZO, and ICOTYDE in new indications will de-risk future revenue streams. | Specific events include FDA regulatory approval for IMAAVY in warm autoimmune hemolytic anemia, data readouts for TECVAYLI in combination with TALVEY, pasritamig, J&J 6143, INLEXZO in high-risk non-muscle invasive bladder cancer, ICOTYDE in psoriatic arthritis, and CAPLYTA in bipolar mania. | Bullish: FDA approvals and positive Phase 3 data readouts for these pipeline assets, indicating expanded market opportunities and strong efficacy/safety profiles. Bearish: Regulatory delays, rejections, or negative/mixed clinical trial results. | Johnson & Johnson's press releases, SEC filings, and investor relations pipeline updates. FDA announcements and clinical trial databases (e.g., ClinicalTrials.gov). | FDA website for drug approvals; medical conference websites (e.g., ASCO, DDW) for data presentations; industry news outlets for pipeline updates. | EvaluatePharma: Pipeline analysis and sales forecasts for new drugs; Citeline: Clinical trial tracking and intelligence. |
| ICOTYDE Launch Momentum and Commercial Coverage | The successful launch and rapid uptake of ICOTYDE, a first-in-class oral peptide for plaque psoriasis, are crucial for Johnson & Johnson's Innovative Medicine segment, demonstrating strong pipeline execution and contributing significantly to future revenue growth, especially as STELARA faces biosimilar competition. | Monitor the number of new patients initiating therapy, unique prescribers, and the percentage of commercial payer coverage. Specifically, watch for continued acceleration beyond the reported 11,000 patients and 6,000 unique prescribers, and commercial coverage exceeding 50%. | Bullish: Continued acceleration in new patient initiations and prescriber count, along with expanding commercial coverage, indicates strong market penetration and positive revenue trajectory. Bearish: A slowdown in patient or prescriber growth, or difficulties in securing broader commercial coverage, would signal challenges in market adoption. | Johnson & Johnson's quarterly earnings calls and associated investor presentations. Company press releases regarding product milestones. | Google Trends: 'ICOTYDE' search volume; healthcare professional forums for discussions on new psoriasis treatments. | IQVIA: Prescription data for ICOTYDE; Symphony Health: New patient starts and market share data for ICOTYDE. |
| MedTech (Abiomed) Performance Recovery and PROTECT IV Data | The recovery of the Abiomed business, particularly Impella usage, is vital for the MedTech segment's overall growth, which experienced a Q2 slowdown due to physician selectivity. Positive clinical data from PROTECT IV will be key to rebuilding physician confidence and driving future growth. | Track Abiomed's sales growth in subsequent quarters, aiming for a return to positive growth and eventually double-digit growth. Monitor any updates or interim analyses from the PROTECT IV trial, which is expected to read out in late 2027. | Bullish: Abiomed sales returning to positive growth and accelerating towards double-digits, or positive interim data/strong physician engagement reinforcing Impella's benefits. Bearish: Continued decline in Abiomed sales or further negative sentiment from clinical trials. | Johnson & Johnson's quarterly earnings calls and investor presentations. Abiomed investor relations updates and medical conference presentations. | ClinicalTrials.gov for PROTECT IV trial updates; industry news and medical journals covering cardiovascular devices. | Spherix Global Insights: Physician sentiment surveys on Impella usage; Definitive Healthcare: Hospital procedure volumes for Impella. |
Key Reported Metrics, Reratings Triggers & ResultsReflects the success of key growth drivers like oncology and immunology, and the strong performance of new product launches, crucial for JNJ's long-term growth
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Innovative Medicine Operational Sales Growth | 6.8% | Reflects the success of key growth drivers like oncology and immunology, and the strong performance of new product launches, crucial for JNJ's long-term growth trajectory. |
| MedTech Operational Sales Growth | 3.6% | Shows the segment's ability to overcome recent challenges (Abiomed, China inventory) and deliver on expected H2 acceleration, contributing to diversified growth. |
| Worldwide Operational Sales Growth | 5.6% | This top-line metric indicates overall company health and the success of new product launches in offsetting STELARA headwinds, driving confidence in future double-digit growth. |
Key QuestionsCan Johnson & Johnson sustain the strong launch momentum of key Innovative Medicine products like ICOTYDE and INLEXZO, and will upcoming H2 2026 pipeline cataly
Can Johnson & Johnson sustain the strong launch momentum of key Innovative Medicine products like ICOTYDE and INLEXZO, and will upcoming H2 2026 pipeline catalysts deliver positive results to offset STELARA's decline and drive accelerated growth?
- Question 2
Will the MedTech segment achieve its anticipated second-half acceleration, particularly with a recovery in Abiomed's performance and strong market adoption of new innovations like the OTTAVA robotic surgical system and VARIPULSE Pro?
- Question 3
Will the event-driven milvexian trials for stroke prevention and atrial fibrillation read out positively, demonstrating a differentiated safety and efficacy profile that can unlock a significant market opportunity and support Johnson & Johnson's long-term double-digit growth target?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. **Accelerating growth and achieving double-digit growth by the end of the decade:** Management repeatedly emphasized the strong Q2 performance, raised guidance, and the expectation of accelerated growth into the second half of 2026 and 2027, with a clear line of sight to double-digit growth by the end of the decade. This is supported by their robust portfolio of 28 products generating over $1 billion in annual sales and a strong pipeline. 2. **Successful new product launches and pipeline innovation:** A significant focus was placed on the strong early momentum of new launches like ICOTYDE, INLEXZO, and RYBREVANT, as well as the continued strong performance of TREMFYA in IBD. Management also highlighted upcoming pipeline catalysts in Innovative Medicine (e.g., IMAAVY, TECVAYLI combinations, pasritamig, J&J 6143, ICOTYDE in psoriatic arthritis, CAPLYTA in bipolar mania) and MedTech (e.g., VARIPULSE Pro, OTTAVA, ETHICON 4000, TECNIS PureSee, ACUVUE OASYS MAX). 3. **Strategic capital allocation and portfolio optimization:** Management discussed prioritizing investments in commercial launches and future innovation, with acquisitions (like Firefly Bio) being an enabler of growth but not a requirement. They also reiterated their commitment to returning capital to shareholders through dividends and the ongoing evaluation of separation options for the Orthopedics business (DePuy Synthes) for mid-2027. | Johnson & Johnson delivered a strong second quarter, exceeding expectations and raising its full-year 2026 guidance. The company is confident in its ability to achieve accelerated growth, driven by a robust portfolio of established products and successful new launches in Innovative Medicine, despite some near-term headwinds in parts of its MedTech segment, particularly Abiomed. The strategic focus on innovation, disciplined execution, and capital allocation is expected to drive long-term value. The tone of the call was overwhelmingly positive and confident. | In Q1 2026, Innovative Medicine operational sales grew 7.4%. MedTech operational sales grew 4.6%. | 1. **Operational sales guidance increase and segment contributions:** Chris Schott from J.P. Morgan asked for more color on the $400 million increase in operational sales guidance, specifically the balance between pharma (Innovative Medicine) and MedTech. *Management Response:* Joe Wolk confirmed it's a fair characterization, with Innovative Medicine moving higher, potentially offset by tempered expectations in MedTech, particularly for Abiomed, where recovery is expected later in the year and into next year. 2. **ICOTYDE launch progress and co-positioning with TREMFYA:** Asad Haider from Goldman Sachs inquired about the detailed progress of the ICOTYDE launch (prescriber count, sampling, formulary negotiations, sales breakout) and how TREMFYA and ICOTYDE are being co-positioned in psoriasis. *Management Response:* Jennifer Taubert expressed thrill with the launch, noting over 11,000 patients and 6,000 unique prescribers, with over 50% commercial coverage ahead of expectations. She clarified that ICOTYDE is positioned as a first-choice systemic treatment, while TREMFYA is the first-choice biologic, especially for psoriatic arthritis, and both are performing well without cannibalization. 3. **MedTech procedure growth and Abiomed performance:** Larry Biegelsen from Wells Fargo raised concerns about U.S. procedure growth and asked about Q2 trends, the outlook for the rest of the year, and specifically about the Abiomed business. *Management Response:* Tim Schmid stated that overall procedure volumes remain stable, with no broad-based slowdown. He acknowledged muted growth in Cardiovascular (Electrophysiology due to China inventory, Abiomed due to physician caution from a neutral clinical trial) but emphasized that three of four MedTech businesses accelerated. He expressed confidence in long-term MedTech growth and expects acceleration in the second half, with Abiomed's recovery taking time but eventually returning to double-digit growth. Joaquin Duato reinforced that Abiomed's temporary situation does not affect the overall growth trajectory. | Worldwide sales increased 5.6% operationally, growing double digits excluding STELARA. Innovative Medicine operational sales grew 6.8% (over 14% excluding STELARA), with DARZALEX up 17.6%, CARVYKTI up 47.7%, TECVAYLI up 56.1%, TALVEY up 62.6%, RYBREVANT plus LAZCLUZE up 61.6%, ERLEADA up 7.6%, TREMFYA up 71%, SPRAVATO up 40%, and CAPLYTA up 70.9%. STELARA declined 55.7%. MedTech operational sales grew 3.6%, with Cardiovascular up 3.1% (Electrophysiology up 3.1%, Abiomed declined 2%, Shockwave up 14.7%), Surgery up 2.3%, Vision up 5.6% (Contact lenses and other products up 6%, Surgical vision up 4.7%), and Orthopedics up 4.2%. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson has 28 products and platforms that each deliver more than $1 billion in annual sales. ICOTYDE has seen over 11,000 patients initiate therapy and 6,000 unique prescribers, with pivotal data for psoriatic arthritis expected later this year and phase III studies in ulcerative colitis and Crohn's disease underway. RYBREVANT has a submitted FDA filing for head and neck cancer to build on existing lung cancer indications. INLEXZO is now being started by one in three eligible patients, with new patient insertions growing 75% quarter-over-quarter, and its NCCN guidelines have been updated to include the papillary population, representing about 80% of BCG unresponsive patients. The company sees significant future opportunities for INLEXZO in BCG experienced (10,000-15,000 patients) and BCG naive (40,000-50,000 patients) populations. VARIPULSE has treated over 85,000 AFib patients worldwide. The Q2 global launch of Shockwave C2 Aero expanded the ability to treat more complex coronary disease. TECNIS PureSee is expanding U.S. availability, and the company is investing over $1 billion to scale U.S. Vision manufacturing, packaging, and distribution capabilities to meet growing demand. CARVYKTI is seeing continued expansion in the community setting with a 25% quarter-over-quarter increase in community sites. milvexian is targeting an estimated 18 million people who should be taking an oral anticoagulant but are not due to bleeding risk. TREMFYA is the share leader in new patient starts for ulcerative colitis and Crohn's disease. | ICOTYDE's performance is outpacing competitors at comparable points in their launches. STELARA's sales declined 55.7% due to share loss from biosimilar competition and increasing adoption of novel classes. CAPLYTA's new patient starts are significantly outpacing the market leader. In electrophysiology, there are competitive PFA pressures. In surgery, there are competitive pressures in energy and endo cutters, and in surgical vision in the U.S. Abiomed faces no current commercialized competitors in heart pumps. TREMFYA is differentiated from other competitive IL-23s and is the share leader in new patient starts for ulcerative colitis and Crohn's disease, despite SKYRIZI holding its own. | There are ongoing concerns about procedure growth in the U.S., with recent data from hospital operators highlighting pressure on certain procedure volumes, particularly in more elective areas of care. However, Johnson & Johnson's diversified business is not seeing evidence of a broad-based slowdown, with volumes generally in line with market trends driven by aging populations, increasing disease prevalence, and ongoing innovation. The company has not observed any meaningful impact on procedure volumes related to the ACA subsidy removals, expecting only minor affordability pressures for a small cohort of patients. | Johnson & Johnson expects 2026 to be a year of accelerated growth, with momentum accelerating into 2027 and beyond, targeting double-digit growth by the end of the decade. The company is on track to be the number one oncology company by 2030, with sales projected to exceed $50 billion. The acquisition of Firefly Bio is expected to close in Q3 2026. MedTech growth is anticipated to be better in the second half of the year, although Abiomed's recovery is expected to extend into next year. Full-year free cash flow is projected to approach $21 billion. Operational sales guidance for the full year 2026 has been raised by $400 million, now expected in the range of 6.5%-7.1%, with a midpoint of $100.6 billion. The adjusted pre-tax operating margin is expected to improve by approximately 75 basis points, and the effective tax rate is projected to be 17.0%-18.0%. Adjusted operational earnings per share guidance has been increased to $11.50-$11.65. The DePuy Synthes business is on track for a mid-2027 separation. | Pharma: | Robotics and digital innovation are unlocking a new era in surgery, exemplified by OTTAVA, the world's first table-integrated robotic surgical system. AI-powered imaging and mapping capabilities are being integrated into electrophysiology with CARTOSOUND SONATA. | “We have the strongest portfolio and pipeline in our 140-year history, with 28 products and platforms that each deliver more than $1 billion in annual sales.” “momentum will accelerate into 2027 and beyond, with line of sight to double-digit growth by the end of the decade.” “ICOTYDE, in particular, has significant early launch momentum, with uptake accelerating and performance outpacing competitors at comparable points in their launches.” “on track to be the number one oncology company by 2030, with sales projected to exceed $50 billion.” “TREMFYA remains the fastest-growing advanced therapy in both Crohn's disease and ulcerative colitis, delivering exceptional overall sales growth of 71% in the quarter.” “We are not dependent on one or two products. We have a broad, durable portfolio that has 28 platforms, each generating more than $1 billion in annual revenue.” “Johnson & Johnson today is a medical innovation powerhouse, uniquely positioned to translate breakthrough science into consistent long-term global growth.” | “Excluding STELARA, we grew double digits in the quarter.” “Abiomed growth slowed in Q2 as a result of increased physician selectivity weighing on procedural volumes.” “STELARA declined 55.7%, driven by share loss due to biosimilar competition, increasing adoption of novel classes, and unfavorable patient mix.” “CV growth was more muted this quarter in both EP and heart recovery.” “Abiomed saw a decline of 2% due to pressures on U.S. procedures driven by usage patterns.” |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-07-15 | Johnson & Johnson reported strong Q2 2026 results, beating revenue and EPS estimates and raising full-year guidance, primarily driven by robust Innovative Medicine growth and new launches. While MedTech faced some headwinds (Abiomed, STELARA's decline), the market reacted positively, with JNJ shares rising post-earnings, reflecting confidence in the company's overall performance and outlook. | Earnings Transcript | Neutral | -1.53% (vs SPY: -1.38%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| JNJ_31eabe8e | during the third quarter of 2026 | 2026-07-01 | 2026-09-30 | Close of Firefly Bio acquisition. | This acquisition strengthens JNJ's leadership in next-generation oncology innovation by adding a proprietary platform designed to target KRAS-driven solid tumors and further diversifying the oncology pipeline. | Ticker | 2026-07-15 | earnings_transcript |